(Q36472269)

14 August 2017

1 reference

title

The metabolic syndrome in polycystic ovary syndrome. (English)

1 reference

polycystic ovary syndrome

14 August 2017

1 reference

1 reference

1 reference

Essah PA

1

1 reference

14 August 2017

Nestler JE

series ordinal

2

1 reference

14 August 2017

publication date

1 March 2006

1 reference

Journal of Endocrinological Investigation

14 August 2017

published in

1 reference

14 August 2017

volume

29

1 reference

14 August 2017

issue

3

1 reference

14 August 2017

page(s)

270-280

1 reference

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Hypertriglyceridemia, insulin resistance, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Low insulin sensitivity (S(i) = 0) in diabetic and nondiabetic subjects in the insulin resistance atherosclerosis study: is it associated with components of the metabolic syndrome and nontraditional risk factors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

The androgenic sex hormone profile is an essential feature of metabolic syndrome in premenopausal women: a controlled community-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Screening women with polycystic ovary syndrome for metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Polycystic ovary syndrome in post-menopausal women--marker of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Self-selected women with polycystic ovary syndrome are reproductively and metabolically abnormal and undertreated

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from C. elegans to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Coronary Heart Disease Risk Factors in Women With Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Altered vascular function in young women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

The prevalence of polycystic ovaries in women with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Obesity as a cardiovascular risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Metformin in polycystic ovary syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Insulin-lowering drugs in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Thiazolidinediones for treatment of polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345554

Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance.

21 January 2018

1 reference

12 December 2020

Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones

1 reference

12 December 2020

Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial

1 reference

12 December 2020

Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis

1 reference

12 December 2020

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

1 reference

12 December 2020

Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women

1 reference

12 December 2020

A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome

1 reference

12 December 2020

Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study

1 reference

12 December 2020

Gamma-glutamyltransferase activity and development of the metabolic syndrome (International Diabetes Federation Definition) in middle-aged men and women: Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort

1 reference

12 December 2020

Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women

1 reference

12 December 2020

Body fat distribution, insulin sensitivity, ovarian dysfunction and serum lipoproteins in patients with polycystic ovary syndrome

1 reference

12 December 2020

Neuropsychiatric lupus and hormones.

1 reference

12 December 2020

Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state?

1 reference

12 December 2020

Effect of weight loss in moderate obesity on plasma lipoprotein and apolipoprotein levels and on high density lipoprotein composition.

1 reference

12 December 2020

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

1 reference

12 December 2020

Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy

1 reference

12 December 2020

Comment on the provisional report from the WHO consultation

1 reference

12 December 2020

Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03345554

1 reference

14 August 2017

1 reference